羟氯喹预防接受治疗的癌症患者COVID-19的随机对照试验研究方案
本研究为三盲、平行组、2-3期随机对照试验,计划纳入60例正在接受治疗的特定类型癌症患者,按1:1随机分配至羟氯喹组(隔日单次口服200mg)或安慰剂组,治疗2个月,主要终点为COVID-19发病率,旨在评估羟氯喹对癌症患者COVID-19的预防效果。
要点
- 研究纳入急性白血病、高危非霍奇金淋巴瘤、非转移性乳腺癌和结肠癌正在治疗的患者。
- 干预为隔日口服羟氯喹200mg或安慰剂,持续2个月,随访监测COVID-19症状。
- 主要终点为癌症治疗期间接受预防性羟氯喹患者的COVID-19发病率。
核心结论
- 本方案旨在评估羟氯喹能否预防正在治疗的癌症患者发生COVID-19,结果尚未报告。
研究设计与样本
- 两臂、平行组、三盲、2-3期随机对照试验。
- 计划总样本量60例,每组30例,分配比1:1。
- 随机化采用在线网站生成的四区组随机排列块。
- 研究在伊朗马什哈德医科大学附属五个中心开展。
- 参与者为15岁以上、正在接受治疗的特定类型癌症患者。
关键数值与推荐
- 干预组隔日口服羟氯喹单次200mg片剂,对照组给予外形、颜色和气味相同的安慰剂,治疗2个月。
- 主要终点为正在接受癌症治疗并接受预防性羟氯喹的患者中COVID-19的发病率。
- 出现COVID-19相关症状时行肺部高分辨率CT和鼻咽拭子RT-PCR检测SARS-CoV-2。
- 纳入标准包括:急性淋巴细胞白血病和急性髓系白血病一线根治性治疗患者、接受白血病方案治疗的高级别非霍奇金淋巴瘤患者、一线治疗的非转移性乳腺癌和结肠癌患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In this study, we will investigate the effect of hydroxychloroquine on the prevention of novel coronavirus disease (COVID-19) in cancer patients being treated. TRIAL DESIGN: This is a two-arm, parallel-group, triple-blind, phase 2-3 randomized controlled trial. PARTICIPANTS: All patients over the age of 15 years from 5 types of cancer will be included in the study. Patients with acute lymphoid and myeloid leukemias in the first line treated with curative intent, patients with high-grade non-Hodgkin's lymphoma treated with leukemia regimens, and patients with non-metastatic breast and colon cancer in the first line of treatment will enter the study. INTERVENTION AND COMPARATOR: Patients are randomly assigned to two groups: one being given hydroxychloroquine and the other is given placebo. During 2 months of treatment, the two groups will be treated with hydroxychloroquine every other day with a single 200-mg tablet (Amin® Pharmaceutical Company, Isfahan, Iran) or placebo (identical in terms of shape, color, and smell). Patients will be monitored for COVID-19 symptoms during follow-up period. If any COVID-19-related signs or symptoms occur, they will be examined, thoroughly, investigated with a high resolution computerize tomography (CT) scan of the lungs and nasopharyngeal swab assessed by RT-PCR for SARS-CoV-2 virus. This study will be performed in five centers affiliated to Mashhad University of Medical Sciences, Mashhad, Iran. MAIN OUTCOMES: The primary end point of this study is to investigate the incidence of COVID-19 in patients being treated for their cancer and receiving prophylactic Hydroxychloroquine. RANDOMIZATION: Randomization will be performed using random permuted blocks. By using online website ( www.randomization.com ), the randomization sequence will be produced by quadruple blocks. The allocation ratio in intervention and control groups is 1:1. BLINDING (MASKING): Participants and caregivers do not know whether the patient is in the intervention or the control group. Those assessing the outcomes and data analyzer are also blinded to group assignment. SAMPLE SIZE: The calculated total sample size is 60 patients, with 30 patients in each group.
引用
- Rahimi H, Allahyari A, Ataei Azimi S, et al. Effect of hydroxychloroquine on COVID-19 prevention in cancer patients undergoing treatment: study protocol for a randomized controlled trial. Trials. 2021. PMID: 34011413. doi:10.1186/s13063-021-05292-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。